Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...
A Thai woman condemned a private hospital in the central province of Samut Sakhon after treatment for nasal polyps left her boyfriend blind.
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Lyra presented the positive ENLIGHTEN 2 Phase 3 results as a Late-Breaking Scientific Oral Presentation at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Congestion - that bunged up, stuffy nose feeling - is usually a fleeting symptom of a cold which lasts for around a week and ...
Women aged 60 years or older had a 32% higher likelihood of CRSsNP diagnosis (OR 1.32). Women had a 37% lower chance of being diagnosed with CRSwNP compared with men (OR 0.63). Biomarker analysis ...
The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...
The Family Health Care Institute bulletin (one of King Hussein Foundation's institutes), on this Sunday, discusses nasal and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback